



# Digestive Diseases and Yale Liver Center Research Seminar

**YaleCME**  
CONTINUING MEDICAL EDUCATION

*Presented by*

Yale School of Medicine's Department of Internal Medicine,  
Section of Digestive Diseases

## “Molecular mechanism for protection against liver failure in human yellow fever infection”

**Paula Vidigal, MD, PhD**

**Associate Professor, Department of Anatomical Pathology,  
Federal University of Minas Gerais (UFMG), Brazil  
Visiting Associate Professor, Yale School of Medicine**

**Tuesday, December 17, 2019  
TAC S-247, 300 Cedar Street  
5:00 - 6:00 pm**

*Host: Michael H. Nathanson, MD, PhD*

**There is no corporate support for this activity. Accreditation:** The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience:** YSM faculty, fellows, and staff, and local GI physicians. **Designation Statement:** The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment:** Update on liver-related manifestations of yellow fever infection from a histological and clinical perspective. Relate and contrast characteristics of acute liver failure in yellow fever and other liver diseases. Discuss novel molecular mechanisms of therapy for yellow fever-related liver disease Reference: Barrett AD, Monath TP. Epidemiology and ecology of yellow fever virus. *Adv Virus Res* 2003;61:291-315. Monath TP. Yellow fever: an update. *Lancet Infect Dis* 2001;1:11-20. Klitting R, Gould EA, Paupy C, de Lamballerie X. What Does the Future Hold for Yellow Fever Virus? (I). *Genes (Basel)* 2018;9. Faria NR, Kraemer MUG, Hill SC, Goes de Jesus J, Aguiar RS, Iani FCM, Xavier J, et al. Genomic and epidemiological monitoring of yellow fever virus transmission potential. *Science* 2018;361:894-899. de Freitas CS, Higa LM, Sacramento CQ, Ferreira AC, et al. Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo. *PLoS Negl Trop Dis* 2019;13:e0007072. Kallas EG, D'Elia Zanella L, Moreira CHV, Buccheri R, et al. Predictors of mortality in patients with yellow fever: an observational cohort study. *Lancet Infect Dis* 2019. Duarte-Neto AN, Cunha MDP, Marcilio I, Song ATW, et al. Yellow Fever and Orthotopic Liver Transplantation: new insights from the autopsy room for an old but reemerging disease. *Histopathology* 2019. Vieira V, Pacheco L, Demetrio L, Balbi E, et al. Liver Transplantation for Acute Liver Failure due to Yellow Fever: A Case Report. *Transplant Proc* 2019;51:1625-1628. Song ATW, Abdala E, de Martino RB, Malbousson LMS, et al. Liver Transplantation for Fulminant Hepatitis Attributed to Yellow Fever. *Hepatology* 2019;69:1349-1352. **Objectives:** Characterize clinical profile of patients that undergo liver failure due to Yellow Fever infection. Characterize orphological aspects of liver histology associated with yellow fever in different clinical outcomes. Evaluate possible molecular mechanisms that could drive clinical evolution of yellow fever infection **Faculty Disclosures:** P. Vidigal - None. M. Nathanson – None. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**